Cullinan Therapeutics, Inc.

NASDAQ:CGEM

Medical - Pharmaceuticals

Healthcare
$9.01 +4.29%

+$0.62 today

Market cap
$584.94M
Beta
0.01
P/E (TTM)
-4.0
EPS (TTM)
-$3.73
52W Low $5.68High $16.74

Volume 1.06M

Average 0.99M

CGEM Weighted Avg Shares

Average number of basic shares outstanding during the period, used to calculate basic EPS.

Cullinan Therapeutics, Inc.NASDAQ: CGEM

Weighted Avg Shares · Q1 FY2026 · quarter ended Mar 2026

Weighted avg shares grows in line with its trailing trend

Q1 FY2026 weighted avg shares of 59.2M shares rose 0.5% year over year, behind the +2.4% change in trailing-twelve-month weighted avg shares. Sequentially, it rose 0.0% from the prior quarter. Over 3 fiscal years it compounded at +9.3% a year.

Context

  • Weighted avg shares increased in 2 of the last 3 fiscal years.
  • FY2025 was the highest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly growth recovers from +0.5% toward the trailing-twelve-month pace of +2.4%.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterMar 2026
59.2M+0.0% QoQ
Last fiscal yearDec 2025
59.05M+9.8% YoY
LTMMar 2026
59.11M+2.4% YoY
Weighted Avg Shares past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+0.5%——
1 year+9.8%——
3-year CAGR+9.3%——
5-year CAGR——
10-year CAGR——

Weighted Avg Shares history

Shares · from the income statement

Latest · FY2025
59.05M USD
Year-over-year change
+9.8%
4-year CAGR
+7.5%

Weighted Avg Shares vs competitors

How CGEM compares with its peers on the latest reported figures

  • CGEM's LTM Mar 2026 weighted avg shares of 59.11M shares is the 9th highest of the 11 companies compared; the peer median is 84.46M shares.
  • Its year-over-year change of +2.4% is the 8th highest of 11, against a peer median of +7.1%.
  • Over three fiscal years its annual growth of +9.3% compares with a peer median of +8.6%.
CGEM Competitors Peer median
Weighted Avg Shares for CGEM and competitors
Company Period LTM YoY 3-year CAGR
LEGNLegend Biotech CorporationLTM Sep 2026185.87M +1.7%+5.0%
ADCTADC Therapeutics S.A.LTM Mar 2026138.66M +34.3%+17.6%
IMTXImmatics N.V.LTM Mar 2026125.95M +14.7%+22.1%
NRIXNurix Therapeutics, Inc.LTM Aug 2026106.95M +29.6%+21.3%
CGENCompugen Ltd.LTM Mar 202693.98M +4.2%+2.6%
XNCRXencor, Inc.LTM Jun 202674.94M +5.1%+7.6%
MGNXMacroGenics, Inc.LTM Mar 202663.24M +0.8%+0.9%
JANXJanux Therapeutics, Inc.LTM Mar 202662.14M +9.2%+14.3%
CGEMCullinan Therapeutics, Inc.LTM Mar 202659.11M +2.4%+9.3%
ALXOALX Oncology Holdings Inc.LTM Mar 202653.9M +2.3%+9.7%
AVBPArriVent BioPharma, Inc. Common StockLTM Mar 202640.11M +19.2%+4.7%
Peer median (excluding CGEM) 84.46M+7.1%+8.6%

Competitors are the stored peer set for CGEM. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue18.94M0000
Cost of Revenue000306K0
Gross Profit18.94M00(306K)0
Gross Margin100.0%————
Research & Development57.75M91.95M148.16M142.9M187.4M
Selling, General & Admin29.15M40.19M42.49M53.71M54.25M
Operating Expenses86.9M(144.65M)191.09M196.61M241.65M
Depreciation & Amortization53K93K310K306K311K
EBITDA(67.43M)(132.04M)(190.34M)(167.15M)(219.57M)
EBITDA Margin-356.0%————
Operating Income(67.95M)144.65M(191.09M)(196.92M)(241.65M)
Operating Margin-358.7%————
Interest Income477K6.61M21.63M29.66M22.21M
Interest Expense00000
Other Income / Expenses469K6.67M21.87M29.46M21.77M
Income Before Tax(67.49M)151.32M(169.22M)(167.46M)(219.88M)
Pre-Tax Margin-356.3%————
Income Tax Expense042.12M(14.12M)117K0
Net Income(65.57M)111.21M(153.16M)(167.38M)(219.88M)
Net Margin-346.1%————
EPS (Basic)(1.48)2.46(3.69)(3.11)(3.72)
EPS (Diluted)(1.48)2.38(3.69)(3.11)(3.72)
Weighted Avg Shares44.29M45.16M41.51M53.77M59.05M
Weighted Avg Shares (Diluted)44.29M46.64M41.55M53.77M59.05M

Cullinan Therapeutics, Inc.

NASDAQ:CGEM

Intrinsic Alpha fair value

Locked

Current Price

$9.01

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.